NASDAQ:ZNTL
Zentalis Pharmaceuticals, Inc.
Zentalis Pharmaceuticals, Inc.'s revenue fell 100.0% in fiscal 2025 to $0. Free cash flow was −$125.2M, and the diluted share count rose 1.1%.Summary generated from Zentalis Pharmaceuticals, Inc.'s SEC filings. Latest annual report filed Mar 26, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$0
Revenue growth−100.0%
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−49.5%
Debt / equityn/a
Free cash flow−$125.2M
FCF marginn/a
Share count change+1.1%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | n/a | 0 | 0 | 67 | 0 |
| Operating income | −217 | −227 | −300 | −191 | −153 |
| Net income | −159 | −237 | −292 | −166 | −137 |
| Free cash flow | −160 | −166 | −208 | −171 | −125 |
Recent filings
- 4Insider transaction report
Oct 1, 2026 - 4Insider transaction report
Aug 19, 2026 - 8-KOther events
Aug 14, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 6, 2026 - 8-KResults of operations and financial condition
Aug 6, 2026 - 8-KResults of a shareholder vote
Jun 18, 2026 - 8-KDirector or officer change
May 27, 2026 - 8-KRegulation FD disclosure
May 21, 2026